# the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

> **NCT06370416** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Henan Cancer Hospital** · enrollment: 41 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Trilaciclib

## Key facts

- **NCT ID:** NCT06370416
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-04-02
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-01-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06370416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06370416, "the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06370416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*